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Does mammalian target of rapamycin or sestrin 1 protein signaling have a role in bone
fracture healing?
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Background/aim: Fracture healing is a complex physiological process that involves a well-orchestrated series of biological events. The
mammalian target of rapamycin (mTOR) and sestrin 1 (SESN 1) play a central role in cell metabolism, proliferation, and survival. The
aim of our study is to present serum mTOR and SESN 1 levels by comparing patients with or without bone fractures. It is also a guide
for further research on the roles of these proteins in fracture healing.
Materials and methods: A total of 34 patients (10 females, 24 males) with bone fractures and 32 controls (10 females, 22 males)
participated in this study. After collecting serum venous blood samples, the quantitative sandwich ELISA technique was used for the
determination of serum mTOR and SESN 1 levels.
Results: The mean serum mTOR level was significantly higher in the fracture group compared to the control group (P = 0.001). However,
SESN 1 levels did not significantly differ between groups (P = 0.913).
Conclusion: We found that serum mTOR levels increased on the first day after fracture compared to the control group. However, we
obtained no significant difference between groups in terms of SESN 1 levels. This study may guide further clinical studies investigating
the potential role of mTOR signaling in the bone healing process.
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1. Introduction
Fractures, mostly arising from injury, are an important
public health burden [1]. Approximately 5%–10% of the
6.2 million fractures occurring annually in the United
States are associated with impaired healing including
delayed healing or nonunion [2].
Fracture healing is a complex physiological process
that involves a well-orchestrated series of biological events
[3]. While our knowledge has vastly expanded, with the
increasing understanding of the multiple factors and
complex pathways involved, many new developments are
anticipated in the years to come. Many local and systemic
regulatory factors such as growth and differentiation
factors, hormones, cytokines, and the extracellular matrix
interact with several cell types including bone and cartilage,
forming primary cells or even muscle mesenchymal cells,
recruited at the fracture-injury site or from circulation [4].
The mammalian target of rapamycin (mTOR) protein,
a 289-kDa serine-threonine kinase, has a central role in
cell metabolism, proliferation, and survival [4,5]. Different

factors including nutrients, growth factors, cellular energy,
and stress regulate mTOR signaling [6]. Insulin and Ras
(Rat sarcoma) signaling pathways are also important
regulators of mTOR signaling activation [7]. The role of
the mTOR pathway has been examined in age-related
pathologies such as neurodegenerative disease, cancer,
heart disease, and metabolic diseases [8–11]. Recent
studies have implicated the potential role of mTOR in
regulating multiple aspects of cartilage development and
preosteoblast differentiation [12,13].
Sestrins (SESN) are highly conserved proteins
that exhibit oxidoreductase activity and therefore the
expression of SESNs is upregulated by DNA damage,
oxidative stress, and hypoxia [14]. Independent of their
antioxidant activity, SESNs are also negative regulators of
mTOR signaling. Several studies revealed the importance
of SESNs in insulin resistance, muscle degeneration,
cardiac dysfunction, mitochondrial pathologies, and
tumors, but little is known about the relationship between
bone fractures and mTOR and SESN-1.
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Previous studies have emphasized the role of mTOR
signaling in bone metabolism [2]. However, to date, we
could find no clinical study investigating serum mTOR
and SESN-1 concentrations in patients with the bone
fracture. We hypothesized that defining serum mTOR
and SESN-1 concentrations in patients with fractures
may demonstrate their potential roles in the bone healing
process. The evaluation of the relationship between these
serum proteins and the pathway occurring in response to
bone fracture may also guide further studies describing
the bone healing process. Therefore, in this study, we
aimed to compare serum mTOR and SESN-1 levels in
patients with or without bone fracture.
2. Materials and methods
2.1. Study population
This cross-sectional study was completed after approval
from our institutional ethical review board and was
conducted in accordance with the Declaration of Helsinki.
Informed consent was obtained from each participant.
Between May 2017 and October 2017, patients who
were admitted to our university hospital and diagnosed
with bone fracture were included in the study. Patients
who were over 65 years old (52 patients) or had systemic
comorbid diseases (25 patients) were excluded from the
study. Patients with high-energy trauma (30 patients)
and multiple fractures were also excluded from the
study group. A control group consisting of healthy
individuals between 18 and 65 years of age was created
by a biochemistry laboratory physician who selected
participants from consecutive healthy individuals. A total
of 34 patients (10 females, 24 males) with bone fractures
and 32 controls (10 females, 22 males) participated in the
study.
2.2. Blood sample collection and analysis
In the fracture group, overnight fasting venous blood
samples were taken from the patients on the first day
of stay in the hospital. The control group consisted
of healthy individuals between 18 and 65 years old
without any comorbid disease and bone fracture. These
individuals were called 1 day before and asked to attend
after overnight fasting. Venous blood samples were
collected from all participants into red-top tubes (Becton
Dickinson, UK). The serum sample tubes were allowed
to clot before centrifugation. After centrifugation at 4
°C for 15 min at 3500 rpm, the serum was aliquoted and
immediately frozen at ˗80 °C (WiseCryo, South Korea).
The quantitative sandwich ELISA technique was used
for the determination of serum mTOR and SESN-1 (YL
Biotech Co. Ltd., China). Tests were performed according
to the manufacturer’s recommendations. Patients with
insufficient samples or incorrect results were excluded
from the study.

2.3. Statistical analysis
The sample size estimation was calculated using GPower
software. The minimum sample size was calculated by
taking into account the large effect size of results for a falsepositive rate of 5% (α = 0.05) and a power of at least 80%
(β = 0.2) [15–17]. Using these parameters and adjusting
for multiple comparisons, we required a minimum sample
size of 26 patients for each group. A total of 32 patients
per group was requested, taking into consideration the
estimated 20% dropout rate (failure of test results); thus,
a total of 64 patients were planned to be enrolled in the
current study.
Statistical analysis was performed using SPSS 22.0
(IBM Corp., USA). Numerical variables are given as
means and standard deviations, and categorical variables
are given as frequencies and percentages. The comparison
of means was completed with the t-test or Mann-Whitney
U-test in accordance with the Shapiro–Wilk normality
test. Comparison of frequencies was performed with the
chi-square test and the Pearson correlation test was used
to evaluate the correlation coefficient between mTOR
and SESN-1 levels in both study groups. P < 0.05 was
considered to be statistically significant.
3. Results
A total of 66 patients (46 females, 20 males) were enrolled
in the study. The fracture group consisted of 34 patients
(24 females, 10 males) with mean age of 45.8 ± 12.6 years
(range: 18 to 64 years). The control group consisted of 32
individuals (22 females, 10 males) with mean age of 47.6
± 10 years (range: 28 to 63 years). The fracture group and
control group had no significant differences in terms of age
or sex (P = 0.728 and P = 0.334, respectively). The mean
serum mTOR level was significantly higher in the fracture
group compared to the control group (P = 0.001). However,
SESN-1 levels did not significantly differ between groups
(P = 0.913) (Table 1). The distributions of fractures in the
fracture group are shown in Table 2.
We observed a significant correlation between mTOR
and SESN-1 levels in the fracture group (P = 0.015, r =
0.412) and in the control group (P = 0.043, r = 0.359).
4. Discussion
Bone fracture is a common injury that may initiate a series
of physiological and pathological reactions. A number of
promising therapeutic approaches have been developed,
such as improvement of internal fixation devices and the
application of novel biological materials; however, delayed
healing or nonunion may occur in 5%–10% of fractures,
adding further to patient morbidity and the expense of
treatment [18]. The improvement of patient morbidity and
reduction of costs is an incentive for the development of
novel therapies to enhance fracture healing [19]. Recent
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Table 1. mTOR and SESN-1 levels of the study groups.
ng/mL

Fracture group (n = 34)

Control group (n = 32)

P-values

mTOR

15.4 ± 6.2 (0.1–22.9)

9.6 ± 5.8 (0.1–22.9)

0.001*

[13.2–17.5]

[7.2–12.1]

19.4 ± 8.7 (0.2–33.8)

19.6 ± 7.3 (0.2–28)

[16.4–22.4]

[16.5–22.7]

SESN-1

0.913*

* P-values according to Student t-test.
Table 2. The distribution of fractures.
Bone

n

%

Humerus

3

8.8

Hand/forearm

2

5.9

Pelvis

4

11.8

Hip

2

5.9

Femur

5

14.7

Tibia

5

14.7

Foot/ankle

5

14.7

Others

8

23.5

Total

34

100

studies have indicated the complexity of the biological
structure of bone [20]. The most important finding of
this study was that serum mTOR levels increased with
fractures while serum SESN-1 levels remained stable
when patients with fractures were compared with a
control group.
mTOR is identified as a key cellular signaling protein
used to respond to diverse environmental stimuli,
control numerous processes that generate or consume
a mass of energy and nutrients, regulate most major
cellular functions, and assist most organisms’ inefficient
transformation between anabolic and catabolic states. It
plays an important role in regulating basic cell behaviors
like growth and proliferation and also has an important
role in bone growth and proliferation [21]. On the other
hand, there is still debate about the effect of mTOR in
osteogenesis. The negative and positive effects of mTOR
inhibition on osteogenesis were also reported [21,22].
Interestingly, the activation of mTOR signaling has also
been found to promote osteoblast differentiation [21]. In
summary, studies showed that mTOR signaling serves as
a double-edged sword in regulating cell differentiation
[21]. These differences appear to depend on cell type
and treatment conditions used [22]. Holstein et al.
reported that rapamycin, an mTOR inhibitor, affected
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early fracture healing and inhibited callus formation in
rats [16]. In another study by Yang et al., the authors
mentioned that the inhibition of mTOR promoted bone
fracture healing in rats [17]. In our study, mTOR levels
were significantly higher in the fracture group compared
to the control group.
Departing from in vitro and animal studies, we
analyzed serum mTOR levels in our patients and found
significantly higher mTOR levels. However, it should
be kept in mind that stress and inflammatory response
secondary to trauma may also lead to the increased
mTOR levels. After fracture, the bone healing process
begins immediately with increases in protein and growth
factor synthesis, which play roles in fracture healing
[23]. Previous studies showed the contribution of mTOR
signaling to protein synthesis [24]. The increased levels
of mTOR in our patient group may be due to increased
protein synthesis secondary to fracture and trauma. In
summary, the current literature agrees on the vital role of
mTOR signaling for bone hemostasis [21].
In terms of demonstration of mTOR levels in fracture
patients, this pathway has been investigated in terms
of musculoskeletal disorders after abruptly leaving the
mTOR pathway. The effect and significance of mTOR had
been previously studied in various areas in the literature
such as neurofibromatosis, rotator cuff tears, pathologies
of nucleus pulposus, and osteosarcoma [25–29]. We think
that this will be a guide for future studies about fractures
in our work.
The SESNs are a class of proteins that are also
induced by stress [14]. Currently, three isoforms of the
SESN family are known: SESN-1, SESN-2, and SESN-3.
Studies have shown that these proteins are important
for the maintenance of metabolic homeostasis, for the
protection of cells against age-related physiological
damage, and, mainly, for the control of adenosine
monophosphate kinase (AMPK)/mTOR signaling [30].
Previous studies showed that inhibition of SESN resulted
in increases of age- and obesity-related pathologies [14].
SESNs suppress oxidative stress and regulate autophagy
[31]. Some conditions have been shown to increase SESN
levels such as hypoxia, oxidative stress, DNA damage,
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and physical exercise [32]. In our study, we also evaluated
levels of serum SESN-1 because of its relationship with
mTOR signaling. According to our results, we found no
significant difference in SESN-1 levels when patients with
fractures were compared to healthy individuals. However,
some studies reported that SESN overexpression potently
suppresses mTOR signaling [30]. We found that there was
a correlation between mTOR and SESN in both groups.
This shows that more studies are needed to evaluate
serum SESN levels on different days after fracture and to
examine more patients.
The main limitation of this study is that serum mTOR
and SESN-1 levels were only measured in the first 24
h after fracture. However, this study is the first in the
literature evaluating serum mTOR and SESN-1 levels in

patients with or without fracture. We also compared two
homogeneous patient populations without any systemic
comorbid disease to exclude other pathologies that may
affect mTOR and SESN signaling pathways.
According to our results, the serum mTOR levels
increased the first day after fracture compared to a control
group. However, we obtained no significant difference
between groups in terms of SESN-1 levels. This study may
guide further clinical studies investigating the potential
role of mTOR signaling in the bone healing process.
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